FDA Inspection 1298166 — Hybio Pharmaceutical Co., Ltd.
The FDA completed an inspection of Hybio Pharmaceutical Co., Ltd. on December 5, 2025 in Shenzhen. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- December 5, 2025
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Shenzhen (China)